Sabal Trust’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $2.18M | Sell |
30,139
-40
| -0.1% | -$2.86K | 0.12% | 98 |
|
|
2024
Q4 | $2.23M | Sell |
30,179
-6,851
| -19% | -$480K | 0.13% | 100 |
|
|
2024
Q3 | $2.44M | Buy |
37,030
+14,311
| +63% | +$1.04M | 0.13% | 91 |
|
|
2024
Q2 | $2.1M | Sell |
22,719
-8,934
| -28% | -$791K | 0.12% | 85 |
|
|
2024
Q1 | $3.02M | Sell |
31,653
-34
| -0.1% | -$2.86K | 0.18% | 73 |
|
|
2023
Q4 | $2.42M | Buy |
31,687
+5
| +0% | +$348 | 0.15% | 73 |
|
|
2023
Q3 | $2.19M | Buy |
31,682
+1,899
| +6% | +$153K | 0.15% | 71 |
|
|
2023
Q2 | $2.81M | Buy |
29,783
+20,792
| +231% | +$1.81M | 0.18% | 65 |
|
|
2023
Q1 | $744K | Buy |
8,991
+90
| +1% | +$7.07K | 0.05% | 80 |
|
|
2022
Q4 | $664K | Sell |
8,901
-18
| -0.2% | -$1.39K | 0.05% | 87 |
|
|
2022
Q3 | $737K | Sell |
8,919
-137
| -2% | -$13.2K | 0.06% | 82 |
|
|
2022
Q2 | $861K | Buy |
9,056
+33
| +0.4% | +$3.42K | 0.06% | 76 |
|
|
2022
Q1 | $1.06M | Buy |
9,023
+141
| +2% | +$15.8K | 0.07% | 71 |
|
|
2021
Q4 | $1.15M | Hold |
8,882
| – | – | 0.07% | 74 |
|
|
2021
Q3 | $1.01M | Hold |
8,882
| – | – | 0.07% | 75 |
|
|
2021
Q2 | $920K | Sell |
8,882
-91
| -1% | -$8.58K | 0.07% | 76 |
|
|
2021
Q1 | $751K | Buy |
8,973
+82
| +0.9% | +$6.93K | 0.06% | 85 |
|
|
2020
Q4 | $811K | Buy |
8,891
+131
| +1% | +$10.9K | 0.07% | 78 |
|
|
2020
Q3 | $699K | Hold |
8,760
| – | – | 0.06% | 79 |
|
|
2020
Q2 | $605K | Hold |
8,760
| – | – | 0.06% | 79 |
|
|
2020
Q1 | $551K | Hold |
8,760
| – | – | 0.06% | 79 |
|
|
2019
Q4 | $681K | Hold |
8,760
| – | – | 0.05% | 85 |
|
|
2019
Q3 | $642K | Hold |
8,760
| – | – | 0.05% | 87 |
|
|
2019
Q2 | $539K | Hold |
8,760
| – | – | 0.05% | 88 |
|
|
2019
Q1 | $559K | Hold |
8,760
| – | – | 0.05% | 89 |
|
|
2018
Q4 | $447K | Hold |
8,760
| – | – | 0.05% | 96 |
|
|
2018
Q3 | $508K | Hold |
8,760
| – | – | 0.04% | 100 |
|
|
2018
Q2 | $425K | Hold |
8,760
| – | – | 0.04% | 105 |
|
|
2018
Q1 | $407K | Hold |
8,760
| – | – | 0.04% | 109 |
|
|
2017
Q4 | $329K | Hold |
8,760
| – | – | 0.03% | 104 |
|
|
2017
Q3 | $319K | Sell |
8,760
-42
| -0.5% | -$1.6K | 0.03% | 109 |
|
|
2017
Q2 | $347K | Buy |
8,802
+42
| +0.5% | +$1.53K | 0.04% | 105 |
|
|
2017
Q1 | $275K | Buy |
+8,760
| New | +$274K | 0.03% | 112 |
|
Other funds holding EW
Sabal Trust's EW Position: Q1 2025 in Review
Sabal Trust reduced its Edwards Lifesciences (EW) stake by 0.13% in Q1 2025, selling an estimated $2.86K and leaving 30,139 shares worth $2.18M. The position accounts for 0.12% of the portfolio, ranked #98.
Sabal Trust first reported a position in EW in Q1 2017 and has held it in 33 quarters since. The position peaked at $3.02M in Q1 2024. 1,205 funds tracked by Wall St. Rank hold EW as of Q1 2025.
- Sabal Trust held 30,139 shares of Edwards Lifesciences worth $2.18M as of Q1 2025.
- Sabal Trust sold 40 Edwards Lifesciences shares in Q1 2025, an estimated $2.86K.
- Edwards Lifesciences made up 0.12% of Sabal Trust's portfolio in Q1 2025, its #98 holding.
- Sabal Trust first reported a position in Edwards Lifesciences in Q1 2017 and has held it in 33 quarters since.
- Sabal Trust's Edwards Lifesciences position peaked at $3.02M in Q1 2024.
- 1,205 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.
Based on Sabal Trust's 13F filing for Q1 2025, filed 23 Apr 2025.